Cellular immunotherapy using dendritic cells against multiple myeloma.

摘要: Cellular therapy with dendritic cells (DCs) is emerging as a useful immunotherapeutic tool to treat multiple myeloma (MM). DC-based idiotype vaccination was recently suggested induce idiotype-specific immune responses in MM patients. However, the clinical results so far have been largely disappointing, and effectiveness of such vaccinations still needs be demonstrated. therapies against may need boosted other sources tumor-associated antigens, potent DCs should recruited increase treatment. both high migratory capacity cytokine production are very important for effective cancer order numbers Th1-type CD4(+) T CD8(+) cytotoxic lymphocytes. The tumor microenvironment also regulation cell growth, proliferation, development therapeutic resistance after In this review, we discuss how efficacy DC can improved. addition, novel treatment strategies that target not only but urgently needed improve outcomes.